DrugDashboards

Zoledronic Acid

Zoledronic Acid · ZOLEDRONIC ACID 5 mg/100mL · Injection, Solution · Intravenous · Dr.Reddy's Laboratories Ltd

NDC 55111-0688-52 · 100 mL in 1 BOTTLE, GLASS · ANDA · View full market →

The short version

10 companies supply this market — deep enough that no single failure threatens the supply. The price is down 28% over the past year, to $0.4774 per mL. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want. Historically, drugs in this position went on to a new shortage within 90 days about 0.4% of the time — roughly 2× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$0.4774per MLinvoice-surveyed acquisition cost · Aug 19, 2026
  • Medicare Part B pays (ASP+6%)$3.36per billing unit (1 MG)HCPCS J3489 · Jul 1, 2026
  • Part D plans paid (avg)$1.48per dosage unitgross, before rebates — matched by drug name · 2024

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$2.50$5.00$7.50Dec 2013Sep 2026$0.4774
30 price points · per MLSource: CMS NADAC

Estimated fill cost

WAC per package, as filed
$150.00
Reported to Texas DSHS · 2026 annual filing · Dr. Reddy's Laboratories, Inc.

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 1 MG
$3.361
HCPCS J3489 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2025)

$41,595
1,266 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

18Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • price down 28% year over year+8
  • sterile injectable+10

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.4%chance of a new FDA shortage posting for zoledronic acid (injectable) in the next 90 days

sterile injectable · OAI inspection at a producing facility (24 months) · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is 2× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $154.07 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA091363
TE code
AP
Approval date
Mar 29, 2013
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

  • Class II · OngoingMay 23, 2024
    Dr. Reddy's Laboratories, Inc.Lack of Assurance of Sterility: Leaking vials
  • Class III · TerminatedSep 12, 2018
    Dr. Reddy's Laboratories, Inc.Failed Impurities/Degradation Specifications: OOS for unknown impurities.
  • Class II · TerminatedMar 3, 2016
    Dr. Reddy's Laboratories, Inc.Lack of Assurance of Sterility; defective seals where the metal silver ring was not attached tightly to the vial

Manufacturers of Zoledronic Acid (Injection, Solution)

LabelerStrengthFirst seenLast seen
Mylan Institutional LLCZOLEDRONIC ACID 5 mg/100mLJul 15, 2026Sep 3, 2026
Sagent PharmaceuticalsZOLEDRONIC ACID .04 mg/mLJul 15, 2026Sep 3, 2026
Dr. Reddy's Laboratories IncZOLEDRONIC ACID 4 mg/100mLJul 15, 2026Sep 2, 2026
Dr.Reddy's Laboratories IncZOLEDRONIC ACID 5 mg/100mLJul 15, 2026Sep 2, 2026
Dr.Reddy's Laboratories LtdZOLEDRONIC ACID 5 mg/100mLJul 15, 2026Sep 2, 2026
Eugia US LLCZOLEDRONIC ACID 5 mg/100mLJul 15, 2026Sep 2, 2026
Fresenius Kabi USA, LLCZOLEDRONIC ACID 5 mg/100mLJul 15, 2026Sep 2, 2026
Gland Pharma LimitedZOLEDRONIC ACID .04 mg/mLJul 15, 2026Sep 2, 2026
Gland Pharma LimitedZOLEDRONIC ACID 5 mg/100mLJul 15, 2026Sep 2, 2026
Meitheal Pharmaceuticals Inc.ZOLEDRONIC ACID 5 mg/100mLJul 15, 2026Sep 2, 2026
Sagent PharmaceuticalsZOLEDRONIC ACID .05 mg/mLJul 15, 2026Sep 2, 2026
Sandoz IncZOLEDRONIC ACID 5 mg/100mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Zoledronic Acid — NDC 55111-0688-52," retrieved September 3, 2026, https://drugdashboards.com/drug/55111068852.

Free to cite with attribution — see how the data is put together.